Children are not just little adults: Recent advances in understanding of diffuse intrinsic pontine glioma biology

Kristin M. Schroeder, Christine M. Hoeman, Oren J. Becher*

*Corresponding author for this work

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Diffuse intrinsic pontine glioma (DIPG) is a high-grade glioma that originates in the pons and is seen exclusively in children. Despite numerous efforts to improve treatment, DIPG remains incurable with 90% of children dying within 2 y of diagnosis, making it one of the leading causes of death in children with brain tumors. With the advent of new genomic tools, the genetic landscape of DIPG is slowly being unraveled. The most common genetic alterations include a K27M mutation in H3.3 or H3.1, which are found in up to 78% of DIPGs, whereas p53 mutations are found in up to 77%. Other recently discovered alterations include amplification of components of the receptor tyrosine kinase/Ras/phosphatidylinositol 3-kinase signaling pathway, particularly platelet-derived growth factor receptor A. Recapitulating such alterations, genetically engineered DIPG preclinical models have been developed, and DIPG xenograft models have also been established. Both models have strengths and weaknesses but can help with the prioritization of novel agents for clinical trials for children with DIPG. As we move forward, it is important that we continue to study the complex and unique biology of DIPG and develop improved preclinical models to increase our understanding of DIPG pathogenesis, allowing translation into successful therapies in the not too distant future.

Original languageEnglish (US)
Pages (from-to)205-209
Number of pages5
JournalPediatric Research
Volume75
Issue number1-2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Glioma
Phosphatidylinositol 3-Kinase
Platelet-Derived Growth Factor Receptors
Mutation
Pons
Receptor Protein-Tyrosine Kinases
Heterografts
Brain Neoplasms
Cause of Death
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

@article{800d2375d4bc4bbcbd12b2575fa134a0,
title = "Children are not just little adults: Recent advances in understanding of diffuse intrinsic pontine glioma biology",
abstract = "Diffuse intrinsic pontine glioma (DIPG) is a high-grade glioma that originates in the pons and is seen exclusively in children. Despite numerous efforts to improve treatment, DIPG remains incurable with 90{\%} of children dying within 2 y of diagnosis, making it one of the leading causes of death in children with brain tumors. With the advent of new genomic tools, the genetic landscape of DIPG is slowly being unraveled. The most common genetic alterations include a K27M mutation in H3.3 or H3.1, which are found in up to 78{\%} of DIPGs, whereas p53 mutations are found in up to 77{\%}. Other recently discovered alterations include amplification of components of the receptor tyrosine kinase/Ras/phosphatidylinositol 3-kinase signaling pathway, particularly platelet-derived growth factor receptor A. Recapitulating such alterations, genetically engineered DIPG preclinical models have been developed, and DIPG xenograft models have also been established. Both models have strengths and weaknesses but can help with the prioritization of novel agents for clinical trials for children with DIPG. As we move forward, it is important that we continue to study the complex and unique biology of DIPG and develop improved preclinical models to increase our understanding of DIPG pathogenesis, allowing translation into successful therapies in the not too distant future.",
author = "Schroeder, {Kristin M.} and Hoeman, {Christine M.} and Becher, {Oren J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1038/pr.2013.194",
language = "English (US)",
volume = "75",
pages = "205--209",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "1-2",

}

Children are not just little adults : Recent advances in understanding of diffuse intrinsic pontine glioma biology. / Schroeder, Kristin M.; Hoeman, Christine M.; Becher, Oren J.

In: Pediatric Research, Vol. 75, No. 1-2, 01.01.2014, p. 205-209.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Children are not just little adults

T2 - Recent advances in understanding of diffuse intrinsic pontine glioma biology

AU - Schroeder, Kristin M.

AU - Hoeman, Christine M.

AU - Becher, Oren J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Diffuse intrinsic pontine glioma (DIPG) is a high-grade glioma that originates in the pons and is seen exclusively in children. Despite numerous efforts to improve treatment, DIPG remains incurable with 90% of children dying within 2 y of diagnosis, making it one of the leading causes of death in children with brain tumors. With the advent of new genomic tools, the genetic landscape of DIPG is slowly being unraveled. The most common genetic alterations include a K27M mutation in H3.3 or H3.1, which are found in up to 78% of DIPGs, whereas p53 mutations are found in up to 77%. Other recently discovered alterations include amplification of components of the receptor tyrosine kinase/Ras/phosphatidylinositol 3-kinase signaling pathway, particularly platelet-derived growth factor receptor A. Recapitulating such alterations, genetically engineered DIPG preclinical models have been developed, and DIPG xenograft models have also been established. Both models have strengths and weaknesses but can help with the prioritization of novel agents for clinical trials for children with DIPG. As we move forward, it is important that we continue to study the complex and unique biology of DIPG and develop improved preclinical models to increase our understanding of DIPG pathogenesis, allowing translation into successful therapies in the not too distant future.

AB - Diffuse intrinsic pontine glioma (DIPG) is a high-grade glioma that originates in the pons and is seen exclusively in children. Despite numerous efforts to improve treatment, DIPG remains incurable with 90% of children dying within 2 y of diagnosis, making it one of the leading causes of death in children with brain tumors. With the advent of new genomic tools, the genetic landscape of DIPG is slowly being unraveled. The most common genetic alterations include a K27M mutation in H3.3 or H3.1, which are found in up to 78% of DIPGs, whereas p53 mutations are found in up to 77%. Other recently discovered alterations include amplification of components of the receptor tyrosine kinase/Ras/phosphatidylinositol 3-kinase signaling pathway, particularly platelet-derived growth factor receptor A. Recapitulating such alterations, genetically engineered DIPG preclinical models have been developed, and DIPG xenograft models have also been established. Both models have strengths and weaknesses but can help with the prioritization of novel agents for clinical trials for children with DIPG. As we move forward, it is important that we continue to study the complex and unique biology of DIPG and develop improved preclinical models to increase our understanding of DIPG pathogenesis, allowing translation into successful therapies in the not too distant future.

UR - http://www.scopus.com/inward/record.url?scp=84900384372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900384372&partnerID=8YFLogxK

U2 - 10.1038/pr.2013.194

DO - 10.1038/pr.2013.194

M3 - Review article

C2 - 24192697

AN - SCOPUS:84900384372

VL - 75

SP - 205

EP - 209

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 1-2

ER -